- Home
- EAF vs EDIT Comparison
EAF vs EDIT Comparison
Compare EAF & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EAF
- EDIT
- Stock Information
- Founded
- EAF 1886
- EDIT 2013
- Country
- EAF United States
- EDIT United States
- Employees
- EAF N/A
- EDIT N/A
- Industry
- EAF Industrial Machinery/Components
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EAF Energy
- EDIT Health Care
- Exchange
- EAF Nasdaq
- EDIT Nasdaq
- Market Cap
- EAF 238.5M
- EDIT 263.7M
- IPO Year
- EAF 1995
- EDIT 2016
- Fundamental
- Price
- EAF $9.92
- EDIT $2.76
- Analyst Decision
- EAF Hold
- EDIT Buy
- Analyst Count
- EAF 6
- EDIT 12
- Target Price
- EAF $17.00
- EDIT $5.40
- AVG Volume (30 Days)
- EAF 217.2K
- EDIT 1.8M
- Earning Date
- EAF 07-25-2025
- EDIT 11-03-2025
- Dividend Yield
- EAF N/A
- EDIT N/A
- EPS Growth
- EAF N/A
- EDIT N/A
- EPS
- EAF N/A
- EDIT N/A
- Revenue
- EAF $508,550,000.00
- EDIT $38,901,000.00
- Revenue This Year
- EAF N/A
- EDIT N/A
- Revenue Next Year
- EAF $19.47
- EDIT N/A
- P/E Ratio
- EAF N/A
- EDIT N/A
- Revenue Growth
- EAF N/A
- EDIT N/A
- 52 Week Low
- EAF $5.50
- EDIT $0.91
- 52 Week High
- EAF $25.30
- EDIT $4.12
- Technical
- Relative Strength Index (RSI)
- EAF 43.00
- EDIT 54.04
- Support Level
- EAF $8.97
- EDIT $2.39
- Resistance Level
- EAF $10.75
- EDIT $2.72
- Average True Range (ATR)
- EAF 0.84
- EDIT 0.18
- MACD
- EAF -0.11
- EDIT -0.01
- Stochastic Oscillator
- EAF 23.00
- EDIT 53.62
About EAF GrafTech International Ltd.
GrafTech International Ltd is a manufacturer of high-quality graphite electrode products essential to the production of EAF steel and other ferrous and non-ferrous metals. The company has only reportable segment, Industrial Materials, is comprised of its two product categories: graphite electrodes and petroleum needle coke products. Petroleum needle coke is key raw material used in the production of graphite electrodes.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.